エピソード

  • 21: The Weekly Dose: Cannabis, Contraceptives, and Advances in Alzheimer Disease and Gonorrhea Treatment
    2025/06/11
    In this episode of Weekly Dose, we cover the latest clinical research, including a study linking cannabis-related ED visits to a higher risk of dementia, and new findings on hormonal contraceptives and postpartum depression. We also explore the FDA’s approval of the first blood test for Alzheimer disease diagnosis, gepotidacin as an oral treatment for gonorrhea, and the growing global burden of atopic dermatitis in older adults. Tune in for a comprehensive overview of these important studies and their clinical implications.
    続きを読む 一部表示
    5 分
  • 20: Weekly Dose from Patient Care Online: Advancements in Colonoscopy, AI for Mammography, and Telemedicine Antibiotic Stewardship
    2025/06/04
    In this episode of Weekly Dose, we round up the latest clinical research, featuring key studies on patient navigation for follow-up colonoscopy, the FDA-approved Teal Wand for at-home cervical cancer screening, and the effectiveness of telemedicine in managing acute respiratory tract infections. We also explore the real-world data on upadacitinib for Crohn disease and the impact of AI in improving mammography accuracy. Tune in for a comprehensive look at these groundbreaking studies and their implications for clinical practice.
    続きを読む 一部表示
    5 分
  • 19: The Weekly Dose from Patient Care: How Medicaid Policies Impact Postpartum Depression Care
    2025/05/22
    In this episode of The Weekly Dose, Patient Care editors speaks with Elizabeth Mollard, PhD, about new research she presented at the 2025 American College of Obstetricians and Gynecologists (ACOG) Annual Clinical & Scientific Meeting that highlighted how Medicaid policy directly impacts postpartum depression (PPD) diagnosis rates. Drawing on national data, Mollard explains that more generous Medicaid coverage—especially extended postpartum eligibility—leads to more frequent diagnoses of PPD, a finding that underscores the critical importance of access to care. The conversation covers clinical implications, the effects of the COVID-19-era Medicaid expansion and wind-down, and practical recommendations for clinicians and policymakers to improve mental health outcomes for postpartum patients.

    Key Points:

    • More robust Medicaid coverage leads to higher rates of PPD diagnosis.
      This is not indicative of higher prevalence, but rather of improved access and identification of women in need of care.

    • Medicaid policy changes during the COVID-19 pandemic offer a natural experiment.
      When postpartum Medicaid coverage was expanded nationally, diagnosis rates rose. After the expansion ended, diagnoses dropped—likely due to decreased access, not decreased incidence.

    • Universal screening should be standard clinical practice.
      Mollard recommends screening beyond the six-week postpartum visit and ensuring continuity of care for those who screen positive.

    • Medicaid must support a full range of postpartum mental health services.
      Coverage should include not only screening, but also counseling, medications like zuranolone, and extended eligibility through 12 months postpartum.

    • Policy gaps leave many women uninsured at a vulnerable time.
      Many working women earn too much to qualify for Medicaid but too little to afford private insurance, making extended postpartum coverage essential to reduce disparities and prevent worsening mental health outcomes.

    続きを読む 一部表示
    5 分
  • 18: Weekly Dose from Patient Care Online: New Findings on BV, Atopic Dermatitis, Colorectal Cancer, and More
    2025/05/07
    In this episode of Weekly Dose, we dive into the most impactful clinical research from the past week on Patient Care, covering key studies across multiple specialties. We begin with a study on the treatment of bacterial vaginosis, highlighting the significant impact of antimicrobial therapy for male partners in reducing recurrence rates. Next, we explore a meta-analysis on the use of dupilumab in treating atopic dermatitis in children, showcasing its effectiveness in reducing disease severity and pruritus. We also cover a groundbreaking study on colorectal cancer risk models for adults aged under 45 years, introducing new ways to personalize screening strategies.

    Additionally, we discuss the EKSTROM trial, which presents data on colchicine’s role in stabilizing coronary plaque and reducing cardiovascular risk. Finally, we look at the FDA’s approval of dupilumab for chronic spontaneous urticaria, offering new hope for patients with persistent symptoms despite antihistamine treatment.

    続きを読む 一部表示
    5 分
  • 17: Medical Economics Pulse, April 4, 2025: CMS Director Oz, autoinjector factory in South Carolina, rural independent practice declines
    2025/04/04
    Hello and welcome to Medical Economics Pulse, a quick-hitting news podcast that keeps busy physicians in the know. We offer concise updates on the most important developments affecting your practice, your bottom line, and the broader health care landscape, delivered to you by our editorial team at Medical Economics.

    It’s Friday, April 4, 2025, and here are today’s headlines:

    Dr. Mehmet Oz, a cardiothoracic surgeon and former television host, has been confirmed by the U.S. Senate as the new administrator of the Centers for Medicare & Medicaid Services (CMS), succeeding Chiquita Brooks-LaSure. While some applaud his communication skills and medical background, others voice strong concern over his history of promoting non-evidence-based treatments and his alignment with controversial policy positions. Pharmacy stakeholders, like the National Association of Chain Drug Stores, see Oz’s appointment as an opportunity to push for reform of pharmacy benefit managers and chronic disease prevention, while critics warn of potential threats to Medicare, Medicaid, and the Affordable Care Act.

    On the innovation front, there’s a big move in South Carolina. SHL Medical has officially opened a state-of-the-art manufacturing facility in North Charleston. The site will specialize in advanced drug delivery systems, including autoinjectors, a growing market driven by the surge in biologics. The new 360,000-square-foot facility, representing a $220 million investment, is designed to manufacture SHL Medical’s autoinjectors used in the treatment of endocrine and metabolic disorders — including GLP-1 therapies — as well as dermatology, musculoskeletal diseases, and other therapeutic areas. This facility also signals a reshoring trend — bringing manufacturing closer to U.S. health care markets, reducing supply chain delays, and potentially improving access and cost-efficiency.

    Finally, the independent physician practice is quietly vanishing from the heart of rural America. According to a recent report from the Physicians Advocacy Institute (PAI), rural areas are seeing a steady decline in small, physician-owned practices. What’s driving this? Financial strain, staffing shortages, and increasing administrative burdens have forced many doctors to either retire early or join larger health systems. For communities already grappling with limited access to care, this shift widens the health care gap, particularly in primary care and preventive services. As this situation gets worse, the medical community may turn to advocacy and push for policies that preserve autonomy and access in these underserved areas.

    And that’s it for today’s Medical Economics Pulse. Be sure to subscribe for new episodes, and read more health business news and expert content at MedicalEconomics.com. Be sure to subscribe to our premiere podcast, “Off the Chart, A Business of Medicine Podcast,” which features lively and informative conversations with health care experts, opinion leaders, and practicing physicians about the challenges facing doctors and medical practices.

    Thanks for tuning in.

    続きを読む 一部表示
    3 分
  • 16: Medical Economics Pulse, April 2, 2025: Medical device industry booming, diabetic medication adherence, advancing digital health
    2025/04/02
    Hello and welcome to Medical Economics Pulse, a quick-hitting news podcast that keeps busy physicians in the know. We offer concise updates on the most important developments affecting your practice, your bottom line, and the broader health care landscape, delivered to you by our editorial team at Medical Economics.

    It’s Wednesday April 2, 2025, and here are today’s headlines:

    First, the medical device industry is on an impressive trajectory. A recent report from BCC Research indicates that the sector is expected to grow at a compound annual growth rate of 9.8%, growing from $810.4 billion in 2024 to reach $1.3 trillion by 2029. This surge is driven by technological advancements, including artificial intelligence and wearable devices, enhancing both efficiency and intelligence in patient care tools. Additionally, the increasing prevalence of chronic diseases and an aging population are amplifying the demand for innovative medical technologies. Will President Trump’s tariffs create headwinds for the device industry? Stay tuned.

    Turning to patient adherence, a concerning study from the University of Virginia Health System reveals that nearly 40% of patients with Type 2 diabetes discontinue their medications within a year of initiation. This trend poses significant health risks and underscores the need for more effective treatment strategies. Researchers advocate for a patient-centered approach that combines medication with continuous glucose monitoring and lifestyle interventions. The goal is to create personalized treatment plans that align with patient preferences, thereby improving adherence and overall health outcomes.

    In the realm of digital health, the American Telemedicine Association and the Digital Therapeutics Alliance have formed the Advancing Digital Health Coalition. This partnership aims to promote the integration of digital health solutions into patient care, emphasizing the importance of innovative technologies in enhancing treatment outcomes. The coalition seeks to focus on four key areas of policy, including federal and state resources for reimbursement, federal regulations, partnerships and business opportunities around the world, and digital interventions to assist patients.

    And that’s it for today’s Medical Economics Pulse. Be sure to subscribe for new episodes, and read more health business news and expert content at MedicalEconomics.com. Be sure to subscribe to our premiere podcast, “Off the Chart, A Business of Medicine Podcast,” which features lively and informative conversations with health care experts, opinion leaders, and practicing physicians about the challenges facing doctors and medical practices.

    Thanks for tuning in.
    続きを読む 一部表示
    3 分
  • 15: Medical Economics Pulse, March 28, 2025: Major HHS restructuring, FDA device approval delays, Medicare and weight-loss medications
    2025/03/28
    Hello and welcome to Medical Economics Pulse, a quick-hitting news podcast that keeps busy physicians in the know. We offer concise updates on the most important developments affecting your practice, your bottom line, and the broader health care landscape, delivered to you by our editorial team at Medical Economics.

    It’s March 28, 2025, and here are today’s headlines:

    The U.S. Department of Health and Human Services (HHS) recently announced plans to cut 10,000 jobs as part of a major reorganization aimed at streamlining operations and reducing costs. While the department claims the move will increase efficiency, it raises concerns about potential disruptions in health care services, regulatory oversight, and public health programs. For physicians, this could translate to longer processing times for Medicare reimbursements, slower policy updates, and administrative inefficiencies. Experts warn that fewer personnel could lead to gaps in regulatory enforcement and delayed responses to emerging health threats. For clinicians, this means staying vigilant about billing issues, policy changes, and patient access challenges that may result from the restructuring.

    Next up, the U.S. Food and Drug Administration (FDA) is also reducing its workforce, which is already having a tangible impact on the review and approval process for medical devices. Physicians relying on new technologies for diagnostics, treatments, and procedures may face significant delays in accessing these innovations. This could hinder physicians’ ability to adopt cutting-edge devices that could enhance patient care and clinical outcomes. For specialists in cardiology, neurology, and surgery, where device innovation plays a critical role, this is especially concerning. Staying updated on regulatory timelines and collaborating with industry representatives will be essential to minimize disruptions in patient care.

    Finally, there’s a hot-button issue gaining momentum: whether Medicare should cover weight-loss medications. A recent study found that a majority of older Americans support coverage for these treatments, citing the potential to reduce obesity-related comorbidities like diabetes and cardiovascular disease. However, the cost of weight-loss drugs remains a major sticking point. Popular medications, such as semaglutide (Wegovy), can cost more than $1,300 per month out-of-pocket. If Medicare were to cover these drugs, analysts estimate it could cost the program billions of dollars annually, sparking concerns over financial sustainability. Physicians may need to advocate for expanded coverage while helping patients navigate cost-effective weight management strategies.

    And that’s it for today’s Medical Economics Pulse. Be sure to subscribe for new episodes, and read more health business news and expert content at MedicalEconomics.com. Be sure to subscribe to our premiere podcast, “Off the Chart, A Business of Medicine Podcast,” which features lively and informative conversations with health care experts, opinion leaders, and practicing physicians about the challenges facing doctors and medical practices.

    Thanks for tuning in.
    続きを読む 一部表示
    3 分
  • 14: Medical Economics Pulse, March 26, 2025: Patients will wait to see their doctor, new tech in maternity care, avoidable deaths rising in America
    2025/03/26
    Hello and welcome to Medical Economics Pulse, a quick-hitting news podcast that keeps busy physicians in the know. We offer concise updates on the most important developments affecting your practice, your bottom line, and the broader health care landscape, delivered to you by our editorial team at Medical Economics.

    It’s March 26, 2025, and here are today’s headlines:

    It’s no secret that patient trust and satisfaction are deeply tied to continuity of care. According to a new study, patients are increasingly willing to wait longer for appointments if it means seeing their own doctor. In fact, more than half of patients expressed a preference for seeing their primary physician rather than being scheduled with another provider for a sooner appointment. This trend highlights a growing demand for familiarity and consistency, which studies have shown can lead to better health outcomes. For physicians, this underscores the importance of strengthening patient-physician relationships. It also raises questions about the need for practice efficiency and scheduling flexibility to accommodate patient preferences.

    Next up, we have an example of technology transforming maternity care. A new platform aims to standardize and modernize maternal health management. The system uses data-driven insights to identify risks and streamline care coordination. By implementing standardized protocols, the technology ensures more consistent care practices across different facilities, reducing variability in maternal health outcomes. For physicians, this represents an opportunity to leverage technology for earlier intervention and improved monitoring of both maternal and fetal health. With the U.S. still grappling with high maternal mortality rates, these innovations could be a game-changer in delivering safer, more reliable care.

    Finally, more Americans die from avoidable causes than citizens of any other high-income country. According to a study in JAMA Internal Medicine, the U.S. has the highest rate of preventable deaths from conditions like diabetes, heart disease, and certain cancers. The report highlights systemic issues, including delayed access to care, inconsistent preventive screening, and fragmented care coordination. For physicians, it reinforces the need for proactive patient engagement, improved chronic disease management, and better coordination with specialists. It also emphasizes the critical role of health policies that support preventive care and access to treatment.

    And that’s it for today’s Medical Economics Pulse. Be sure to subscribe for new episodes, and read more health business news and expert content at MedicalEconomics.com. Be sure to subscribe to our premiere podcast, “Off the Chart, A Business of Medicine Podcast,” which features lively and informative conversations with health care experts, opinion leaders, and practicing physicians about the challenges facing doctors and medical practices.

    Thanks for tuning in.
    続きを読む 一部表示
    3 分